Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105126 | 0.84 | DHFR (0.48) | DHFRALDH1A1KDM4EGAAMAPT | |
| SCHEMBL2103486 | 0.82 | FGFR1 (0.50) | DHFRMAOB | |
| SCHEMBL649075 | 0.79 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL9029161 | 0.79 | TSHR (0.48) | ALDH1A1KDM4ERAB9AL3MBTL1 | |
| SCHEMBL2102562 | 0.79 | HRH3 (0.51) | ALDH1A1MPORAB9AL3MBTL1 | |
| SCHEMBL2100697 | 0.78 | DPYD (0.41) | DPYDBCHEMAOBMEN1KMT2A | |
| SCHEMBL16432914 | 0.77 | MAOB (0.49) | DPYDBCHECYP4F2CYP4A11MAOB | |
| SCHEMBL2100722 | 0.77 | LMNA (0.45) | ALDH1A1 | |
| SCHEMBL4948276 | 0.77 | DPYD (0.53) | DPYDBCHECYP4F2CYP4A11DHFR | |
| SCHEMBL4427549 | 0.76 | KCNH2 (0.55) | MAOBMAOAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101374832-B | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101374832-A | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | DPYD 4019/4885BCHE 528/4885CYP4F2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.